Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

227.31 -0.52 (-0.23%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 805,975
Open 228.03
Bid (Size) 227.00 (200)
Ask (Size) 230.01 (200)
Prev. Close 227.83
Today's Range 226.00 - 229.88
52wk Range 186.05 - 282.15
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup ↗
Via Chartmill
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors ↗
Via Chartmill

Performance

YTD
+6.6%
+6.6%
1 Month
-13.6%
-13.6%
3 Month
-15.1%
-15.1%
6 Month
-0.4%
-0.4%
1 Year
+14.3%
+14.3%

More News

Read More
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup ↗
Via Chartmill
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate ↗
Via Chartmill
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗
Via Chartmill
Topics Earnings
News headline image
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
From Eyconis Inc.
Via GlobeNewswire
News headline image
Ascendis Pharma A/S Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Via The Motley Fool
Topics Regulatory Compliance
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis (ASND) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
Via MarketMinute
Topics Economy
News headline image
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗
Via Chartmill

Frequently Asked Questions

Is Ascendis Pharma A/S - Ordinary Share publicly traded?
Yes, Ascendis Pharma A/S - Ordinary Share is publicly traded.
What exchange does Ascendis Pharma A/S - Ordinary Share trade on?
Ascendis Pharma A/S - Ordinary Share trades on the Nasdaq Stock Market
What is the ticker symbol for Ascendis Pharma A/S - Ordinary Share?
The ticker symbol for Ascendis Pharma A/S - Ordinary Share is ASND on the Nasdaq Stock Market
What is the current price of Ascendis Pharma A/S - Ordinary Share?
The current price of Ascendis Pharma A/S - Ordinary Share is 227.31
When was Ascendis Pharma A/S - Ordinary Share last traded?
The last trade of Ascendis Pharma A/S - Ordinary Share was at 10/01/26 04:00 PM ET
What is the market capitalization of Ascendis Pharma A/S - Ordinary Share?
The market capitalization of Ascendis Pharma A/S - Ordinary Share is 12.99B
How many shares of Ascendis Pharma A/S - Ordinary Share are outstanding?
Ascendis Pharma A/S - Ordinary Share has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.